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PET imaging-guided chemogenetic silencing reveals
a critical role of primate rostromedial caudate in
reward evaluation
Yuji Nagai1, Erika Kikuchi1, Walter Lerchner2, Ken-ichi Inoue3, Bin Ji1, Mark A.G. Eldridge2, Hiroyuki Kaneko1,
Yasuyuki Kimura1, Arata Oh-Nishi1, Yukiko Hori1, Yoko Kato1, Toshiyuki Hirabayashi1, Atsushi Fujimoto1,
Katsushi Kumata4, Ming-Rong Zhang4, Ichio Aoki5, Tetsuya Suhara1, Makoto Higuchi1, Masahiko Takada3,
Barry J. Richmond2 & Takafumi Minamimoto1
The rostromedial caudate (rmCD) of primates is thought to contribute to reward value
processing, but a causal relationship has not been established. Here we use an inhibitory
DREADD (Designer Receptor Exclusively Activated by Designer Drug) to repeatedly and
non-invasively inactivate rmCD of macaque monkeys. We inject an adeno-associated viral
vector expressing the inhibitory DREADD, hM4Di, into the rmCD bilaterally. To visualize
DREADD expression in vivo, we develop a non-invasive imaging method using positron
emission tomography (PET). PET imaging provides information critical for successful
chemogenetic silencing during experiments, in this case the location and level of hM4Di
expression, and the relationship between agonist dose and hM4Di receptor occupancy. Here
we demonstrate that inactivating bilateral rmCD through activation of hM4Di produces a
signiﬁcant and reproducible loss of sensitivity to reward value in monkeys. Thus, the rmCD is
involved in making normal judgments about the value of reward.
DOI: 10.1038/ncomms13605 OPEN
1 Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and
Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. 2 Laboratory of Neuropsychology, National Institute of Mental Health, National Institutes of
Health, Bethesda, Maryland 20892, USA. 3 Systems Neuroscience Section, Primate Research Institute, Kyoto University, Inuyama, Aichi 484-8506, Japan.
4Department of Radiopharmaceuticals Development, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science
and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. 5 Department of Molecular Imaging and Theranostics, National Institute of Radiological
Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan. Correspondence and
requests for materials should be addressed to T.M. (email: minamimoto.takafumi@qst.go.jp).
NATURE COMMUNICATIONS | 7:13605 | DOI: 10.1038/ncomms13605 | www.nature.com/naturecommunications 1
T
he rostromedial caudate (rmCD) is a subregion of the
striatum that receives strong projections from frontal
limbic areas, especially the orbitofrontal cortex (OFC)1.
Recording studies in this region have revealed neuronal response
signalling information concerning the expected reward size. The
same population of neurons exhibits relatively weak selectivity
to movements/actions2,3. These anatomical and physiological
characteristics support the hypothesis that the rmCD is part
of the brain’s reward circuit4. However, a causative role of the
rmCD in reward evaluation and decision-making has not
been established in primates. Unlike sensory and motor
representations that are strongly lateralized, representations of
reward and related functions seem to have relatively little
lateralization, and thus function can remain unperturbed when
a critical brain region is damaged unilaterally5. Therefore, any
inactivation approach should target the rmCD bilaterally.
Chemogenetic techniques, such as DREADDs (Designer
Receptors Exclusively Activated by Designer Drugs), offer a
means to repeatedly and non-invasively inactivate multiple brain
sites simultaneously. When a modiﬁed human M4 muscarinic
acetylcholine receptor (hM4Di) is expressed in a target neuronal
population, activity of such neurons is temporarily suppressed
after systemic delivery of a biologically inert inducer compound,
for instance, clozapine-N-oxide (CNO)6. To achieve the intended
chemogenetic silencing, the inhibitory DREADD, hM4Di,
needs to be accurately localized to a target structure and
expressed at a sufﬁciently high level to silence host neurons.
In addition, the inducer compound must be available at a
concentration high enough to bind and activate the DREADD.
Previously, it was only possible to determine the extent of
receptor expression through post-mortem histological analysis,
and to determine ligand-binding characteristics ex vivo.
Here we report a non-invasive method for imaging DREADD
expression in vivo using a PET ligand, 11C-labelled clozapine
([11C]CLZ)7. Macaque monkeys received injections of a
DREADD-expressing viral vector into the rmCD, were scanned
with [11C]CLZ-PET to visualize the sites and level of DREADD
expression in vivo, and then also with a blocking protocol to
measure DREADD receptor occupancy by CNO (Fig. 1a,b). The
resulting data can be applied to determine an appropriate dose of
CNO for subsequent behavioural experiments with chemogenetic
silencing. We show that CNO activation of the hM4Di receptor
expressed bilaterally in the rmCD successfully produces a clear and
reproducible decrease in sensitivity to reward value in monkeys.
Results
In vivo PET visualization of hM4Di expression in rmCD.
Three monkeys (#171, #184, #190) were trained to perform a
‘reward-size’ task (Fig. 1c). Each trial in this task began when the
monkey touched a lever, which was followed by the appearance of
a visual cue that signalled the size of the upcoming reward (1, 2, 4
or 8 drops; Fig. 1d). To obtain a liquid reward, the monkeys had
to release the lever when a visual target changed colour from red
to green. Here, as in previous studies, the monkeys’ error rates
(proportion of trials with incorrect responses; releasing the lever
too early or too late) were related to the value of the upcoming
reward8.
The monkeys received bilateral injections of adeno-associated
virus serotype 2 (AAV2), containing a construct with a
cytomegalovirus (CMV) promoter that expresses the hM4Di
receptor without protein tags (AAV-hM4Di) into the rmCD of
both hemispheres (Fig. 1a; one pair of injections in #171 and
#190; two pairs of injections in #184; see below regarding #184).
The combination of AAV2 and CMV results in neuron-speciﬁc
expression in monkeys9. We veriﬁed that activation of the
hM4Di receptor with CNO caused neuronal silencing in vitro
(Supplementary Fig. 1).
To localize and monitor the hM4Di expression in vivo,
we applied [11C]CLZ-PET. DREADD-PET visualization was
validated with two other monkeys expressing hM4Di in one side
of the striatum (monkeys #157 and #127; Supplementary Fig. 2).
We conﬁrmed that the striatal sites visualized by PET (ligand
uptake4120% of baseline) were coextensive with those showing
the hM4Di expression histochemically (Supplementary Fig. 2).
The [11C]CLZ-PET scans in monkey #171 showed increased
[11C]CLZ binding in the bilateral rmCD at day 45 post
AAV-hM4Di, at which point the expression seemed to have
reached a plateau (Fig. 2a,b).
Chemogenetic inactivation of rmCD impairs reward estimation.
To determine the extent to which hM4Di receptor is occupied by
CNO as a function of dose, we performed [11C]CLZ-PET scans
10min after i.v. bolus CNO doses of 1, 3 and 10mg kg 1 in
monkey #157. Striatal uptake at the hM4Di-vector injection site
diminished as the CNO dose increased, whereas uptake was
unchanged on the contralateral control side (Fig. 2c). The relation
between occupancy of hM4Di and CNO dose was approximated
by a Hill function (Fig. 2d). We chose a CNO dose of 3mg kg 1,
because it yieldsB50–60% receptor occupancy of hM4Di, and is
not converted to a signiﬁcant amount of CLZ (Supplementary
Fig. 3).
We examined behavioural effects of chemogenetic silencing of
rmCD in monkey #171. We conﬁrmed that the CNO treatment
(3mg kg 1, i.v.) produced comparable receptor occupancy at
rmCD (Fig. 2d,e). The CNO treatment increased the overall error
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Figure 1 | Experimental design. (a) Three monkeys received AAV-hM4Di vector injections into the rmCD. (b) [11C]CLZ-PET was performed to
monitor DREADD expression in vivo and to measure occupancy of DREADD with CNO. (c) While monkeys performed reward-size task, CNO was
administered intravenously to induce chemogenetic silencing in the rmCD. (d) Cue-reward-size pairing in reward-size task.
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analysis of variance (ANOVA), main effect of treatment,
F4,66¼ 6.5, P¼ 1.6 10 4; post hoc TukeyHSD, P¼ 2.7 10 11,
CNO versus Post vector; P¼ 3.4 10 6, CNO versus Vehicle;
Fig. 3a). The increase in error rates was observed throughout the
testing session (that is, 15–115min after CNO injection; three-
way ANOVA, main effect of treatment, F1,9¼ 10.7, P¼ 0.0095) in
parallel with the increase in error over time (interaction with
time, F4,216¼ 9.2, P¼ 0.073; main effect of time, F4,216¼ 15.5,
P¼ 3.4 10 11) (Fig. 3d). On the day following CNO injection,
the error rates had returned to baseline levels (post hoc
TukeyHSD, P¼ 0.20; Post CNO versus Post vector; Fig. 3a),
showing that the functional effect of CNO treatment lasted
o24 h. There was no difference in the baseline error rates—i.e., in
the absence of CNO—between pre- and post-vector injection
(post hoc TukeyHSD, P¼ 0.92; Fig. 3a), suggesting that the
behavioural effect of hM4Di expression alone was negligible.
In the other two monkeys (#190 and #184) the [11C]CLZ-PET
scans also showed increased [11C]CLZ binding in the bilateral
rmCD (Fig. 4a,b, day 29 after second injection in #184 and day 31
after injection in #190). The CNO treatment increased the overall
error rates in these monkeys (main effect of treatment, Po0.01,
Fig. 4c,d).
For all three monkeys, the reaction times in correct trials were
not affected by CNO administration (two-way ANOVA, main
effect of treatment, F1,134¼ 0.12, P¼ 0.72). The monkeys
generally reached satiety and stopped initiating new trials within
the 100min testing period. The total reward earned was slightly,
not signiﬁcantly, less in the CNO treatment sessions (ANOVA,
main effect of treatment, F1,32¼ 3.1, P¼ 0.09). These results
suggest that the increase in overall error rates observed after
chemogenetic silencing was not due to a general reduction in
attention or drive.
To quantify the effect of rmCD silencing on reward evaluation,
we analysed the relationship between the error rates and reward
size. The error rates (E) in this task have an inverse relation with
reward size (R)8. Here we used a modiﬁed version of the inverse
function, E ¼ cRþ b, where c is a free-ﬁtting parameter that
quantiﬁes reward requirement for a given performance and b
quantiﬁes a shift to a ﬂatter portion of the curve. This equation
reportedly explains alterations of reward evaluation in monkeys
with OFC ablations10. This equation also described the error rates
in the current study (R2¼ 0.91±0.09, mean±s.d., for example,
Fig. 3a, dotted curves). Compared with vehicle treatment, CNO
treatment increased parameter b (Fig. 3b, CNO), reﬂecting a loss
of sensitivity to reward contrast. CNO treatment also increased
parameter c (Fig. 3c, CNO), indicating that more reward is
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Figure 2 | PET monitoring hM4Di expression in bilateral rmCD.
(a) Coronal [11C]CLZ-PET image taken 45 days after hM4Di vector
injection (only for area over 120% striatal baseline), overlaid on MR image
for monkey #171. (b) Time course of [11C]CLZ uptake at the rmCD after
vector injection for monkey #171. Coloured ticks indicate behavioural
testing condition on the corresponding day: P, C, PC and V indicate post
vector, CNO, post CNO and vehicle, respectively. (c) Coronal [11C]CLZ-PET
images at the bilateral putamen level in monkey #157. PET images at
non-treatment and after the administration of 1, 3 and 10mg kg 1 doses of
CNO (i.v.) are shown from top to bottom. (d) Occupancy of hM4Di
receptor is plotted as a function of CNO dose. Red and blue represent data
obtained from monkeys #157 and #171, respectively. Dotted curve is the
best-ﬁt Hill function to the data from #157. ED50 and n indicate the CNO
dose achieving 50% occupancy and Hill coefﬁcient, respectively. R240.99.
(e) [11C]CLZ-PET images at bilateral rmCD level in monkey #171 at
non-treatment (upper) and after administration of 3mg kg 1 doses of
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Figure 3 | Behavioural effect of PET-monitored chemogenetic silencing.
(a) Performance of reward-size task of monkey #171. Error rate
(mean±s.e.m.) as a function of reward size is plotted. Performance of
pre-viral vector injection (Pre-vector, green), 415 days after viral injection
(post vector, black), CNO treatment (3mg kg 1, i.v., red), on the day after
CNO treatment (post CNO, orange), and treatment with vehicle without
CNO (blue). Dotted curves represent best ﬁt of the inverse model, E ¼ cRþ b ,
where E and R are error rate and reward size, and b and c are free
parameters shown in b,c that quantify the shift of inverse relation and the
impact of reward size on error rates, respectively. R240.75. (d) The time
course of CNO induced behavioural effects in monkey #171. Error rate was
plotted as a function of reward size for each 20-min period for CNO (red)
and vehicle treatment (blue).
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rates). Thus, chemogenetic inactivation of the rmCD leads to
decreases in the sensitivity to reward.
In the two control monkeys without AAV-hM4Di vector
injections, CNO treatment alone had no effect on performance
(main effect of treatment, P40.05; Supplementary Fig. 4a).
In another two monkeys that received AAV-HA-hM4Di
vector injections into the rmCD bilaterally, the [11C]CLZ-PET
scans failed to detect increased uptake at the injection sites
(Supplementary Fig. 4b, top; day 29 and 38 after vector injections,
respectively). Subsequent CNO administration did not affect
error rates in these monkeys (main effect of treatment, P40.05;
Supplementary Fig. 4b, bottom). One of the three monkeys
with a behavioural effect due to the DREADD inactivation
initially failed to show any effect of CNO treatment on
performance (#184; main effect of treatment, F1,4¼ 0.006,
P¼ 0.94; Supplementary Fig. 4c, bottom). A [11C]CLZ-PET scan
exhibited increased uptake in one hemisphere that was located
dorsal to the intended target (Supplementary Fig. 4c, top; day 31
after the 1st AAV-hM4Di injection). This led us to give a second
set of injections, after which a PET scan showed increased uptake
that covered the intended rmCD target (Fig. 4a), and we then
obtained the behavioural results described above (Fig. 4c).
After several CNO treatments, [11C]CLZ-PET still showed
increased uptake in the bilateral rmCD (#171, 121%, day 95,
Fig. 2b; #184, 125%, day 83 after second injection), suggesting
that repetitive CNO treatment in our study did not produce
signiﬁcant on-going tachyphylaxis of hM4Di-DREADD
receptors. DREADD activation once a week is insufﬁcient to
rule out tachyphylaxis on a shorter timescale.
Comparison with pharmacological inactivation. To compare
the behavioural effects of chemogenetic inactivation with those of
pharmacological inactivation, we injected the GABAA receptor
agonist muscimol into the rmCD in two other monkeys
(#181 and #182; Fig. 5a). X-ray computed tomography (CT)
images visualizing injection cannulae conﬁrmed that the sites of
muscimol injection (Fig. 5b–d) corresponded to those of hM4Di
expression (cf. Fig. 2a). For both monkeys, pharmacological
inactivation of the bilateral rmCD increased the overall error rates
(main effect of treatment, Po0.01; Fig. 5c,d, bottom) and
diminished the sensitivity of reward, as indicated by increases in
parameters b and c (Fig. 5e,f, muscimol). Unilateral inactivation
of the rmCD produced a trend toward increased overall error rates
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Figure 4 | Chemogenetic silencing of rmCD produced loss of reward
sensitivity. (a,b) In vivo hM4Di expression in monkeys #184 and #190,
respectively. Coronal image of [11C]CLZ-PET overlaid on structural MR
image, taken at day 31 and day 29 after vector injection, respectively.
Scale bar, 5mm. PET images for area over 120% striatal baseline are shown.
(c,d) Effect of chemogenetic silencing of rmCD on performance of
reward-size task. Error rate (mean±s.e.m.) as a function of reward size is
plotted for CNO treatment (red) and vehicle control sessions (blue). Dotted
curve is the best ﬁt of inverse function (R240.80).
Muscimol (3–4 µg µl–1, 2 µl) Cannulae
#181



























































Figure 5 | DREADD versus muscimol inactivation. (a) Illustration of
intended muscimol injection sites. (b) Identiﬁcation of injection sites using
CT. (c) (top) Location of a pair of muscimol injections for each session
indicated by different coloured dots on a coronal MR image for monkey
#181. Scale bar¼ 5mm. (bottom) Behavioural performance for baseline
(black) and inactivation of bilateral rmCD by muscimol (cyan). Error rates
(mean±s.e.m.) are shown as function of reward size. Dotted curve is the
best ﬁt of inverse function. (d) Muscimol injection sites and behaviour for
monkey #182. (e,f) Comparison of treatment-induced changes in best-ﬁt
parameters of b and c, respectively. DREADD indicates data obtained from
monkeys #171, #184 (after second injection), and #190. Muscimol indicate
the data obtained from monkeys #181 and #182. NC denotes data obtained
from negative cases (n¼6) that are shown in Supplementary Fig. 4. Points
indicate values derived from individual subjects, while bars indicate average
across subjects. Subscripts i and c indicate best-ﬁt parameters for
inactivation and control condition, respectively.
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but did not change the reward-size sensitivity (Fig. 5e,f,
included in NC), suggesting that abnormal reward evaluation was
ascribable to bilateral rmCD inactivation. Thus, chemogenetic
silencing appeared to produce behavioural changes similar to
pharmacological inactivation at the same location.
Discussion
In the present work, we demonstrated that repeatedly inactivating
the rmCD through the use of CNO to activate the inhibitory
DREADD, hM4Di, produced a clear and reproducible loss of
sensitivity to reward value in the decision-making of monkeys.
The rmCD inactivation did not seem to decrease attention or
drive; the reaction times and the total reward earned were
unaffected. This decreased reward sensitivity is in line with the
presumed function of the rmCD, a structure receiving strong
input from several prefrontal cortical areas that are crucial to
reward-related behaviour1. The decreased sensitivity to relative
value during rmCD silencing is similar to that seen after bilateral
removal of the OFC10. It has been suggested that the rmCD
integrates information from the prefrontal areas11, including the
OFC, an area known to be responsible for motivational and
reward-related information12–17. Silencing the rmCD with
muscimol produced the same behavioural effect as silencing
with DREADD, providing conﬁrmation that the effect is speciﬁc
to the perturbation of neuronal activity in this region, and not an
artefact of the technique employed. From these experiments, and
given the lack of effect when the DREADD failed to express at the
intended target (cf. Supplementary Fig. 4), we conclude that this
small region we identify as rmCD is essential for assessing
predicted reward values.
Because temporary inactivation of the rmCD using the hM4Di
receptor versus muscimol produced similar effects, either of the
silencing methods might have been sufﬁcient for our experiment.
However, chemogenetic silencing offers several advantages over
pharmacological inactivation, so we were eager to pursue its
application. First, once the hM4Di-DREADD expression becomes
stable (that is, 4–6 weeks following injection of the vector), local
inactivation can be induced repeatedly by systemic CNO
administration, whereas local pharmacological inactivation
requires implanted or repeated insertion of a cannula, making
it likely that there will be ongoing mechanical damage. Second,
because the neurons expressing hM4Di-DREADD form a stable
population, every inactivation is virtually identical to every other
one, whereas the effects of local pharmacological inactivation vary
session-by-session due to variation in the spread and exact dose,
making it difﬁcult to know precisely which tissue has been
affected. The region expressing hM4Di-DREADD can be
identiﬁed by post-mortem analysis with histochemical staining
at cellular resolution. Third, with multiple viral vector injections,
extensive regions of tissue can be affected18, or, as shown here,
discontinuous regions can be inactivated simultaneously via
single systemic administration of the inducer. Fourth, cell-speciﬁc
promoters9 or pathway-selective expression systems19,20
can drive expression of hM4Di-DREADD in speciﬁc neuronal
subsets or pathways, enabling manipulation of a neural circuit
deﬁned by a cell type, an anatomical connection, or other
markers. Finally, synaptic silencing via localized microinfusion of
CNO at a site distal to the neurons expressing hM4Di-DREADD
enables pathway-selective functional analysis21.
We also report that the hM4Di receptor can be imaged in vivo
with [11C]CLZ-PET. PET imaging provides a means to visualize
the location of and measure the stability of hM4Di-DREADD
expression in this subcortical region (cf. Supplementary Fig. 2).
Knowing whether the correct region has been affected when the
expression has been stabilized is of great advantage for
conducting behavioural experiments, especially in nonhuman
primates, which often require the investment of considerable
time, effort and other resources in each individual subject. The
potential value of this approach is shown by the correlation
between weak/mistargeted DREADD expression and the absence
of effect on behaviour (cf. Supplementary Fig. 4b,c); these results
indicate that PET visualization of DREADD expression would
make a useful screening procedure prior to beginning a series of
behavioural experiments, and especially longitudinal studies.
[11C]CLZ-PET also provides a way of measuring in vivo
DREADD receptor occupancy by CNO. Based on the dose-
occupancy curve (cf. Fig. 2d), we chose a dose of 3mg kg 1 CNO,
yieldingB60% receptor occupancy, to carry out our behavioural
studies. This dose of CNO produced a repeatable behavioural
modulation in reward sensitivity. At this dose there was no CLZ
in cerebrospinal ﬂuid (CSF). We did not see signs of other
behavioural effects of CNO such as sedation or loss of motivation
as were seen at a higher dose (10mg kg 1) in our previous
study18. This latter observation is relevant because there is some
evidence that in humans and guinea pigs, at least, CNO can be
metabolized to CLZ, an atypical antipsychotic drug with sedative
effects22,23. Because of the concern over side effects, other
DREADD agonists such as compound 21 or Perlapine24 should
be investigated for their potential utility in primates, and perhaps
in the long run in humans.
The success in imaging the hM4Di receptor with [11C]CLZ
almost certainly depends on good permeability of the blood–
brain barrier by CLZ and the high afﬁnity of the hM4Di receptor
for CLZ25. The baseline brain uptake of [11C]CLZ-PET reﬂects a
modest afﬁnity (B10 nM of Ki) of CLZ for many innate
receptors, including serotonergic, dopaminergic, adrenergic,
histaminergic and muscarinic receptors6. Despite the resulting
possibility of interference by its binding to such receptors, uptake
at hM4Di-expressing regions was about 20% higher than the
natural background in ﬁve monkeys, a sufﬁciently high signal-to-
noise ratio to permit reliable detection using the reference
method (cf. Fig. 2a). As more speciﬁc ligands are developed, the
utility of PET for monitoring gene expression in the brain should
improve considerably.
In summary, using the CNO-activated hM4Di-DREADD, we
have revealed that the rmCD is involved in making normal
judgments about the value of reward, which is largely consistent
with previous anatomy and single-neuron recording studies. The
mechanism by which DREADDs work, and their potential for
covering a large and diffuse population of neurons, as well as the
capability of verifying DREADD expression by PET imaging
before undertaking functional CNO activation experiments,
ought to make this system an attractive tool for application to
long-term behavioural studies, and potentially to clinical settings
in the future.
Methods
Subjects. The subjects were 12 macaque monkeys (two cynomolgus (Macaca
fascicularis; #127, #157), eight rhesus (Macaca mulatta; #152, #178, #181, #182,
#183, #184 #190, #199) and two Japanese monkeys (Macaca fuscata; #171, #174);
4.2–9.8 kg; age 5–14 years; all were male except #174). All experimental procedures
were carried out in accordance with the Guide for the Care and Use of Laboratory
Animals (National Research Council of the US National Academy of Sciences) and
were approved by the Animal Care and Use Committee of the National Institute of
Radiological Sciences. The monkeys were kept in individual primate cages in an
air-conditioned room. A standard diet, supplementary fruits/vegetables and a tablet
of vitamin C (200mg) were provided daily.
Viral vector production. The AAV2-CMV-hM4Di (AAV-hM4Di; Fig. 1a) and
AAV2-CMV-HA-hM4Di (AAV-HA-hM4Di) vectors were produced by the helper-
free triple transfection procedure and was puriﬁed by afﬁnity chromatography
(GE Healthcare). Viral titre was determined by quantitative PCR using Taq-Man
technology (Life Technologies). The transfer plasmid (pAAV-CMV-hM4Di-WPRE)
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was constructed by inserting hM4Di fragment and WPRE sequence into an AAV
backbone plasmid (pAAV-CMV, Stratagene).
The Lenti-hSyn::hM4Di-CFP (Lenti-hM4Di-CFP) and Lenti-syn::CFP
(Lenti-CFP) vectors were produced as previously described18,26. I293T cells
(Lenti-X Invitrogen 632180, Life Technologies) were transfected with the
Lenti-backbone plasmid and packaging plasmids (gift from Didier Trono; Addgene
plasmids #12260 and #12259). Supernatant was replaced with Ultraculture medium
(Invitrogen). The lentiviral vector containing supernatant was collected and
concentrated (Beckman S28 rotor, at 22,000 r.p.m.), and aliquots were stored at
 80 C. Virus titre was determined by quantitative PCR as described previously9.
The transfer plasmid (hM4Di-CFP gene) was constructed by replacing the
mCherry sequence with cerulean cyan ﬂuorescent protein (CFP) in the hM4Di-
mCherry sequence27, and cloned into the Lenti-syn::GFP vector9 by replacing the
GFP sequence.
Surgical procedures and viral vector injections. The monkeys used for vector
injection and viral vector, volume, titre and location of injection are summarized in
Supplementary Table 1. Prior to surgery, overlay magnetic resonance (MR) and CT
images were created using PMOD image analysis software (PMOD Technologies
Ltd, Zurich, Switzerland) to estimate stereotaxic coordinates of the target brain
structures. Under isoﬂurane general anaesthesia (1–2%), the monkeys underwent a
surgical procedure to open burr holes (B8mm diameter) for the injection needle.
Three monkeys (#171, #184 and #190) had bilateral injections into the rmCD, with
3 ml of AAV-hM4Di (2.0 1013 particles per ml) injected in each side. Two other
monkeys (#182 and #183) had bilateral injections of 3 ml of AAV-HA-hM4Di
(1.8 1013 particles per ml) into the rmCD on each side. Two monkeys (#127 and
#157) had bilateral injections into the lateral putamen, with 30 ml of Lenti-hM4Di
(2 109 particles per ml) in one side and 30 ml of Lenti-CFP (2 109 particles per
ml) in the other. Viruses were pressure-injected by 50 or 10-ml Hamilton syringe
(Model 705 RN or 701 RN, Hamilton) with a 30-gauge injection needle and a fused
silica capillary (450 mm OD) to create a step about 500 mm away from the needle tip
to minimize backﬂow. The Hamilton syringe was mounted into a motorized
microinjector (IMS-10, Narishige) that was held by manipulator (Model 1460,
David Kopf, Ltd.) on the stereotaxic frame. After the dura mater was opened about
5mm, the injection needle was inserted into the brain and slowly moved down
2–3mm beyond the target and then kept stationary for 5min, after which it was
pulled up to the target location. The injection speed was set at 0.5 ml min 1. After
each injection, the needle remained in situ for 15min to minimize backﬂow along
the needle.
For muscimol injection, two monkeys (#181 and #182) had surgery under
isoﬂurane anaesthesia (1–2%) to implant a head-ﬁxation device and two chambers
(CRIST Instrument Company., Inc.) targeting the caudate nucleus at a 20 angle in
the coronal plane.
Drug administration. CNO (Toronto Research) was dissolved in 2.5% of dimethyl
sulfoxide (DMSO) in saline to a ﬁnal volume of 6ml. For behavioural testing, a
catheter was placed in the saphenous vein while the monkey was seated in a
primate chair. CNO (3mg kg 1) or the vehicle alone (2.5% DMSO) was
administered at a rate of 0.2ml s 1 intravenously via the catheter 15min before
behavioural testing. For PET occupancy studies, CNO solution (doses 1, 3 and
10mg kg 1) was administrated intravenously via a saphenous vein catheter 10min
before PET imaging. For in vitro electrophysiology, CNO was diluted into 1 mM
with artiﬁcial CSF. Fresh CNO solution was prepared on the day of usage.
Muscimol (Sigma) was dissolved in saline at a dose of 3 mgml 1 (#181) or
4 mgml 1 (#182). The solution (2ml) was injected at a rate of 0.2–0.4 ml min 1
through an injection-recording cannula (350 mm OD, BRC Inc. Japan) inserted
stereotaxically into each hemisphere. Each cannula was held by an oil-drive
manipulator (MO-97A, Narishige). Behavioural testing was started after the
injection was completed. Locations of injection cannulae were visualized using CT
scans after each muscimol injection session, and the locations of the tip were
mapped onto MR image using PMOD.
Radiosynthesis and PET imaging. [11C]CLZ was radiosynthesized based on the
described protocol28, and its radiochemical purity and speciﬁc radioactivity at the
end of synthesis exceeded 95% and 37GBqmmol 1, respectively. PET scans were
performed using a microPET Focus 220 scanner (Siemens Medical Solutions,
USA), which yields a 258mm diameter 76mm axial ﬁeld of view (FOV) and a
spatial resolution of 1.3mm full width at half maximum at the centre of FOV29.
The monkey was anaesthetized with isoﬂurane (1–2%) during all PET procedures.
Emission scans were acquired for 90min in a three-dimensional list mode after
bolus injection of [11C]CLZ (265–405MBq) intravenously via a saphenous vein
catheter. A transmission scan using a spiralling 68Ge-68Ga point source was
performed for correction of attenuation before injection of the radioligands. All
list-mode data were sorted into three-dimensional sinograms, which were then
Fourier-rebinned into two-dimensional sinograms (framesminutes; 5 1, 5 2,
5 3 and 12 5). Images were thereafter reconstructed with ﬁltered back-
projection using a Hanning ﬁlter cut-off at the Nyquist frequency (0.5mm 1).
Volumes of interest (VOIs) were placed manually on a series of coronal slices of
individual MRI. VOI for the baseline striatal reference region was located to cover
all striatal regions excluding ﬁve coronal sections centred on the injection sites
(that is, needle tracks). For the time course analysis, the target and control VOIs for
putaminal injections were deﬁned as follows: target VOI: the area above 120%
baseline striatum in the ﬁnal image (taken at day 72 and 575 for #127 and #157,
respectively); control VOI: the corresponding contralateral area. For rmCD
injections, the target VOI was located in the lower half of the CD along with the
needle track (cf. Fig. 1c). Each VOI was placed on the PET images to calculate the
standardized uptake value (SUV), as the concentration of radioactivity in the VOI
(Bq cm 3) body weight (g)/injected radioactivity (Bq) averaged between 30 and
90min after injection of the radioligand using PMOD. We then calculated the
uptake ratio to the baseline striatum and expressed this as % striatal baseline.
Estimates of fractional occupancy (Occ; cf. Fig. 3d) were derived with regard to
non-treatment as,
Occ ¼ URSNT URSCNO
URSNT  100 ;
where URSCNO and URSNT indicate uptake ratio (%) of target to baseline striatum
under CNO pretreatment and non-treatment conditions, respectively. The





where ED50 and n indicate the CNO dose achieving 50% occupancy and the Hill
coefﬁcient, respectively (cf. Fig. 2d).
Validation of PET visualization for hM4Di-DREADD expression. To validate
the PET visualization of striatal hM4Di expression, we targeted the central
putamen because it has the largest volume among the three striatal subregions
(putamen, caudate and ventral striatum), and the baseline uptake of [11C]CLZ in
these regions did not differ (N¼ 3 monkeys; one-way ANOVA, F2,3¼ 0.008,
P40.99). Two monkeys were injected with a lentiviral vector expressing hM4Di
fused with CFP under the neuron-speciﬁc promoter synapsin (Lenti-hM4Di-CFP)
in the right putamen, and a control lentiviral vector (Lenti-CFP) in the left
putamen (Supplementary Fig. 2a,b). We performed a [11C]CLZ-PET scan with a
monkey (#157) at 82 days after injection. Focal high uptake (46 SUV) was found
in the right putamen compared with the left (Supplementary Fig. 2c). Post-mortem
immunohistochemical examination showed that hM4Di-CFP-positive neurons
were found at the injection site (Supplementary Fig. 2f), where high uptake was
seen in [11C]CLZ-PET (4120% baseline striatal uptake, Supplementary Fig. 2d,e).
The high uptake of [11C]CLZ at the injection site was similar from days 82 to 575
after injection (Supplementary Fig. 2g), suggesting that hM4Di expression levels
were high and stable during this period. We found that increased [11C]CLZ uptake
had reached a plateau by day 46 in the second monkey #127 (Supplementary
Fig. 2h–k). Thus, PET imaging enabled us to characterize the location and stability
of DREADD expression in the striatum.
MR imaging and CT scans. MR imaging and CT scans were performed under
general anaesthesia (intravenously continuous infusion of propofol 0.2–0.6mgkg 1
per minute, or pentobarbital sodium 15–30mg kg 1, i.v.). MR images were
obtained with a 7T 40 cm-bore Avance-I system (KOBELCO/Bruker Biospin)
or a 1.5T Philips GYROSCAN Interna. The following sequences were used for 7T:
three or four sets of FLASH sequence (TR¼ 660.0ms, TE¼ 13.37ms, slice
thickness¼ 1.1mm, matrix¼ 512 512, ﬂip angle¼ 20, FOV¼ 150mm,
NEX¼ 1, number of slices 24). The sequences for 1.5T: three-dimensional
T1-weighted imaging (TR¼ 30ms, TE¼ 6ms, matrix¼ 512 512, FOV¼ 256
mm, slice thickness¼ 1.0mm without slice gap, number of slices¼ 60). CT scans
were obtained using cone-beam CT system (Accuitomo170, J.MORITA CO.,
Japan), which operated with tube voltage¼ 90 kVp, tube current¼ 5mA, exposure
time¼ 17.5 s, FOV¼ 140mm diameter 100mm height, voxel size 0.25
0.25 0.5mm3, and a grey intensity of 16 bits.
Behavioural testing and analysis. A total of seven monkeys were used for
behavioural testing. All monkeys had been trained to perform colour discrimina-
tion trials in the cued multi-trial reward schedule task for more than 3 months.
Task control and data acquisition were performed using the REX program. The use
of an automated system eliminated the need for experimenters to be blind to
treatment. In this study, we used a reward-size task as described previously8
(Fig. 1c). A monkey initiated a trial by touching the bar. A visual cue and a red
target sequentially appeared. After a variable interval, the red target turned green.
If the monkey released the bar between 200 and 1,000ms, a reward of 1, 2, 4 or
8 drops of liquid reward (1 drop¼B0.1ml) was delivered immediately after the
signal turned to blue. If the monkey released too early (B200ms after the green
target appeared) or failed to respond within 1 s after the green target appeared, we
regarded the trial as an ‘error trial’; the trial was aborted and the trial was repeated
after the 1s inter-trial interval. The visual cue presented at the beginning of the
trial indicated the number of drops for the reward (Fig. 1d). In this task, our
behavioural measurement for the expected outcome value was the proportion of
error trials. Since the monkeys were able to perform the task correctly in nearly
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every trial when the reward size was not assigned, an error trial is regarded as a
trial in which the monkeys are not sufﬁciently motivated to release the bar
correctly8. Before each testing session, the monkeys were subject to B22 h of
water restriction without any behavioural testing. Each testing session continued
for 100min, although most monkeys had reached satiety and ceased to initiate
trials by 90min.
Three and two monkeys received bilateral injection of AAV-hM4Di vector and
AAV-HA-hM4Di vector, respectively. Two monkeys were given muscimol
injections, and two monkeys served as non-operated controls. All monkeys had
been trained with the reward-size task for at least 3 weeks. For vector-injection
monkeys, pre-vector baseline data were collected for 15–23 sessions, and
post-vector data collection began 15 days after the vector injection. CNO and
vehicle treatment were tested no more than once per week. For muscimol-injection
monkeys, after recovery from the surgery of head post and chamber (at least
2 weeks), muscimol injection was performed once per week. Non-treatment
baseline data were collected in the same week of the injection except for the day
following the injection. Similarly, behavioural data for non-operated controls were
collected on the day of CNO treatment (CNO; four sessions per monkey) and on
the day without treatments (baseline).
Error rate for each reward size was calculated for each daily session. We
used the error rates to estimate the level of motivation, as the error rates of these
tasks (E) were inversely related to the value for action8. In the reward-size task,
we used an inverse function,
E ¼ c
Rþ b ;
where E is error rate, R is reward size, c and b are constants. We ﬁtted the inverse
function to the data by sum-of-squares minimization. The coefﬁcient of
determination (R2) is reported as a measure of the goodness-of-ﬁt.
We also performed repeated-measures ANOVA to test the effect of
treatment reward size or treatment reward size time from injection on error
rates. Tukey’s HSD multiple comparison tests were conducted as a post hoc test.
The arcsine transformation was used to normalize the distribution of binomial data
(that is, error rates) before statistical analysis30.
Details on data acquisition and analysis for histology, bioavailability of
CNO/CLZ and electrophysiology are presented in the Supplementary Methods.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
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